Page 6 - Nasdaq Bmea News Today

Biomea Fusion (NASDAQ:BMEA – Get Rating) had its price target raised by investment analysts at EF Hutton Acquisition Co. I from $22.00 to $33.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. EF Hutton Acquisition Co. I’s price target suggests a potential upside of […]

EF Hutton Acquisition Co. I restated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Get Rating) in a report published on Tuesday, Benzinga reports. The firm currently has a $22.00 price target on the stock. Several other brokerages also recently weighed in on BMEA. HC Wainwright restated a buy rating and set a […]

Biomea Fusion (NASDAQ:BMEA – Get Rating)‘s stock had its “buy” rating restated by equities research analysts at Keefe, Bruyette & Woods in a research note issued to investors on Friday, Benzinga reports. They currently have a $22.00 price target on the stock. Keefe, Bruyette & Woods’ price target indicates a potential upside of 39.24% from […]

Biomea Fusion (NASDAQ:BMEA – Get Rating)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Thursday, Stock Target Advisor reports. They currently have a $16.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 259.55% from the company’s current price. […]

Biomea Fusion (NASDAQ:BMEA – Get Rating) had its target price dropped by investment analysts at Piper Sandler from $25.00 to $16.00 in a report released on Friday, The Fly reports. Piper Sandler’s price objective would indicate a potential upside of 174.91% from the company’s previous close. Separately, Zacks Investment Research raised shares of Biomea Fusion […]

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to...

Biomea Fusion (NASDAQ:BMEA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat […]

Shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) have received an average rating of “Buy” from the six brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among […]

Shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) have been assigned an average rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month […]

Biomea Fusion (NASDAQ:BMEA – Get Rating) and RedHill Biopharma (NASDAQ:RDHL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Earnings and Valuation This table compares Biomea Fusion and […]